原发性肝癌患者介入治疗前后SE-CAD,CA19-9和VEGF水平的变化

Changes of Serum SE-CAD,CA19-9 and VEGF Levels in Patients with Primary Hepatic Cancer Before and After Intervention Therapy

为探讨原发性肝癌患者介入治疗前后,血清可溶性上皮钙粘蛋白(SE-CAD),糖类抗原19-9(CA19-9)和血管内皮生长因子(VEGF)水平的变化,本文应用RIA测定了32例患者血清CA19-9的水平,ELASA测定SE-CAD和VEGF水平,并与35名健康人相比较。患者介入治疗前后SE-CAD,CA19-9和VEGF水平明显高于正常组(P<0.01)。介入治疗后30例中,有20例在6个月以后没有复发,患者血清三项指标回落至正常范围,介入治疗后6个月,10例复发患者血清SE-CAD,CA19-9和VEGF水平的变化与患者的病情和愈后密切相关,有一定的实用价值。

To explore the changes of serum SE-CAD, CA19-9 and VEGF levels in patients with primary hepatic cancer before and after intervention therapy, serum CA19-9 levels were detected by RIA, and serum SE-CAD and VEGF levels by ELISA in 32 patients and 35 healthy controls. The results showed that serum SE-CAD, CA19-9 and VEGF levels in patients before intervention therapy were significantly higher than those in control group（P〈0.01）. Twenty of 30 patients after 6 months of intervention therapy showed no sign of recurrence of cancer, and their serum SE-CAD, CA19-9 and VEGF levels dropped to normal range. The changes of serum SE-CAD, CA19-9 and VEGF levels in other 10 patients with recurrence of cancer were closely related to the disease process of primary hepatic cancer and might be regarded as useful values.